InVenti Selected as Preferred Provider for Pfizer
inVentiv Health Inc., a contract research organization (CRO), has been selected by Pfizer as one of its preferred partners in the delivery of clinical operations services to support Pfizer’s portfolio.
inVentiv Health, comprised of a CRO and a contract commercial organization, is now a preferred partner in Pfizer's sourcing strategy for global clinical operations services. The agreement term is until June 8, 2019 and provides Pfizer with the right to extend the term for up to an additional two years. Financial terms of the agreement were not disclosed.
As a preferred provider, inVentiv has expanded its clinical operations presence with Pfizer and is focused on therapeutic excellence in the areas of oncology, pain, neuroscience and respiratory and data and technology-driven efficiencies.
Source: inVentiv Health